ANTITUBERCULOSIS AGENTS IN HIV INFECTED PERSONS W/ TB

患有结核病的艾滋病毒感染者的抗结核药物

• 批准号: 6305379
• 负责人: ROBERT KALAYJIAN
• 金额: $ 1.92万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305379
• 关键词: HIV infections; antitubercular agents; clinical research; comorbidity; drug screening /evaluation; ethambutol; human subject; human therapy evaluation; isoniazid; pharmacokinetics; pyrazinamide; tuberculosis

This is a multicenter, pharmacokinetic study whereby HIV-infected subjects with culture-confirmed tuberculosis (TB), who are treated with any 2 or more of the following : rifampin, INH, ethambutol, orpyrazinamide, will have serum drug concentration determinations performed at two time points, in an effort to learn more about the absorption and the pharmacokinetics of these drugs in these subjects. Blood specimens will be collected at 2, 6, and 10 hours after the administration of the study medication, once between days 10-14 of a phase of daily treatment and once while on an intermittent dose regimen.

这是一项多中心药代动力学研究，对经培养确诊结核病 (TB) 的 HIV 感染受试者，接受以下任意 2 种或多种治疗：利福平、异烟肼、乙胺丁醇、奥吡嗪酰胺，将在两个时间点进行血清药物浓度测定，以了解更多有关这些药物在这些药物中的吸收和药代动力学的信息。 科目。将在施用研究药物后 2、6 和 10 小时采集血样，在每日治疗阶段的第 10-14 天之间采集一次，在间歇剂量方案中采集一次。